<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362595</url>
  </required_header>
  <id_info>
    <org_study_id>12-375B</org_study_id>
    <nct_id>NCT01362595</nct_id>
  </id_info>
  <brief_title>Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia</brief_title>
  <acronym>LeucineDBA</acronym>
  <official_title>The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and possibility of giving the amino acid, leucine, in
      patients with Diamond Blackfan anemia(DBA)who are on dependent on red blood cell
      transfusions.

      The leucine is expected to produce a response in patients with DBA to the point where red
      blood cell production is increased. Red cell transfusions can then be less frequent or
      possibly discontinued.

      The investigators will study the side effects, if any, of giving leucine to DBA patients.
      Leucine levels of leucine will be obtained at baseline and during the study.

      The drug leucine will be provided in capsule form and taken 3 times a day for a total of 9
      months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leucine will be provided to participants in the form of a capsule and will be taken three
      times daily.

      Blood hemoglobin levels will be monitored every 3-4 weeks for 9 months.

      The entire study will last 12-15 months in length.

      Subjects must be two years of age or older and on transfusion for more than six months prior
      to enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Leucine in Transfusion dependent patients with Diamond Blackfan Anemia</measure>
    <time_frame>Patients will take leucine for 9 months. The study is expected to take 12-15 months to complete.</time_frame>
    <description>The primary outcome is the type of response observed at 9 months (and 6 months). Response to treatment can be one of the following:
Complete response (CR): Hb &gt; 9 gm/dL and transfusion-independence as defined in DBA
Partial response (PR): Hb &lt; 9 gm/dL and increased reticulocyte count to greater than 1% and any increase in transfusion interval from baseline. (Baseline reticulocytes range from 0.1 to 0.5 and transfusions are usually performed every 3 weeks. An increase of reticulocyte counts to over 1 to 1.5% and any increase in transfusion interval will be considered a PR.)
No response (NR): no change in transfusion requirements and no significant change in Hb or reticulocytes (or any response that does not satisfy the conditions of either a PR or CR)
Progression: worsening of disease as defined by the need for more frequent transfusions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of leucine in transfusion-dependent DBA patients</measure>
    <time_frame>Total study 12-15 months</time_frame>
    <description>Secondary outcomes include safety parameters such as type, frequency, and severity of adverse events and relationship to leucine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diamond Blackfan Anemia</condition>
  <condition>Blackfan Diamond Syndrome</condition>
  <condition>DBA</condition>
  <condition>Congenital Hypoplastic Anemia</condition>
  <condition>Pure Red Cell Aplasia</condition>
  <arm_group>
    <arm_group_label>Leucine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No alternative treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucine</intervention_name>
    <description>Dosage of leucine will be dependent on body surface area (BSA):
leucine 700 mg/m2/dose by mouth three times a day</description>
    <arm_group_label>Leucine</arm_group_label>
    <other_name>leucine, L-leucine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with Diamond Blackfan anemia as published in British Journal of Hematology

          -  transfusion dependent

          -  age 2 years and older

          -  adequate renal function

          -  adequate liver function

          -  negative B-HCG if patient is a menstruating female and documentation of adequate
             contraception

          -  signed informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to branched chain amino acids

          -  Diagnosis of an inborn error of amino acid metabolism disorder

          -  Prior hematopoietic stem cell transplantation

          -  Pregnancy, or plans to become pregnant during duration of trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrianna Vlachos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore- Long Island Jewish Medical Center; Cohen Children's Medical Center of NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri-Columbia Women's and Children's Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dbar.org</url>
    <description>Diamond Blackfan Anemia Registry - a registry for patients with DBA in North America</description>
  </link>
  <link>
    <url>http://www.dmaf.org</url>
    <description>Daniella Maria Arturi Foundation is a family sponsored group which facilitates research for DBA.</description>
  </link>
  <link>
    <url>http://www.dbafoundation.org</url>
    <description>The DBA foundation is a family sponsored organization who raise funds for research and provides emotional support to families.</description>
  </link>
  <reference>
    <citation>Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B, Dahl N. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999 Feb;21(2):169-75.</citation>
    <PMID>9988267</PMID>
  </reference>
  <reference>
    <citation>Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM, Vlachos A, Atsidaftos E, Ball SE, Orfali KA, Niewiadomska E, Da Costa L, Tchernia G, Niemeyer C, Meerpohl JJ, Stahl J, Schratt G, Glader B, Backer K, Wong C, Nathan DG, Beggs AH, Sieff CA. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006 Dec;79(6):1110-8. Epub 2006 Nov 2.</citation>
    <PMID>17186470</PMID>
  </reference>
  <reference>
    <citation>Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007 Dec;28(12):1178-82.</citation>
    <PMID>17647292</PMID>
  </reference>
  <reference>
    <citation>Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer P, Esposito D, Beggs AH, Schneider HE, Grabowska A, Ball SE, Niewiadomska E, Sieff CA, Vlachos A, Atsidaftos E, Ellis SR, Lipton JM, Gazda HT, Arceci RJ. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008 Sep 1;112(5):1582-92. doi: 10.1182/blood-2008-02-140012. Epub 2008 Jun 5.</citation>
    <PMID>18535205</PMID>
  </reference>
  <reference>
    <citation>Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Zaucha JM, Glader B, Niemeyer C, Meerpohl JJ, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008 Dec;83(6):769-80. doi: 10.1016/j.ajhg.2008.11.004.</citation>
    <PMID>19061985</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):377-82. Review.</citation>
    <PMID>11563775</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Federman N, Reyes-Haley C, Abramson J, Lipton JM. Hematopoietic stem cell transplantation for Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Bone Marrow Transplant. 2001 Feb;27(4):381-6.</citation>
    <PMID>11313667</PMID>
  </reference>
  <reference>
    <citation>Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006 May 1;46(5):558-64.</citation>
    <PMID>16317735</PMID>
  </reference>
  <reference>
    <citation>Ozsoylu S. Oral megadose methylprednisolone for Diamond-Blackfan anemia. Blood. 1994 Nov 1;84(9):3245-7.</citation>
    <PMID>7949199</PMID>
  </reference>
  <reference>
    <citation>Bernini JC, Carrillo JM, Buchanan GR. High-dose intravenous methylprednisolone therapy for patients with Diamond-Blackfan anemia refractory to conventional doses of prednisone. J Pediatr. 1995 Oct;127(4):654-9.</citation>
    <PMID>7562296</PMID>
  </reference>
  <reference>
    <citation>Buchanan GR; International Diamond-Blackfan Anemia Study Group. Oral megadose methylprednisolone therapy for refractory Diamond-Blackfan anemia. International Diamond-Blackfan Anemia Study Group. J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):353-6.</citation>
    <PMID>11563769</PMID>
  </reference>
  <reference>
    <citation>Tötterman TH, Nisell J, Killander A, Gahrton G, Lönnqvist B. Successful treatment of pure red-cell aplasia with cyclosporin. Lancet. 1984 Sep 22;2(8404):693.</citation>
    <PMID>6147711</PMID>
  </reference>
  <reference>
    <citation>Williams DL, Mageed AS, Findley H, Ragab AH. Cyclosporine in the treatment of red cell aplasia. Am J Pediatr Hematol Oncol. 1987 Winter;9(4):314-6.</citation>
    <PMID>3125756</PMID>
  </reference>
  <reference>
    <citation>Seip M, Zanussi GF. Cyclosporine in steroid-resistant Diamond-Blackfan anaemia. Acta Paediatr Scand. 1988 May;77(3):464-6.</citation>
    <PMID>3389144</PMID>
  </reference>
  <reference>
    <citation>Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989 Jun;72(2):278-84.</citation>
    <PMID>2503027</PMID>
  </reference>
  <reference>
    <citation>Splain J, Berman BW. Cyclosporin A treatment for Diamond-Blackfan anemia. Am J Hematol. 1992 Mar;39(3):208-11.</citation>
    <PMID>1546717</PMID>
  </reference>
  <reference>
    <citation>Monteserin MC, Garcia Vela JA, Oña F, Lastra AM. Cyclosporin A for Diamond-Blackfan anemia: a new case. Am J Hematol. 1993 Apr;42(4):406-7.</citation>
    <PMID>8493997</PMID>
  </reference>
  <reference>
    <citation>Alessandri AJ, Rogers PC, Wadsworth LD, Davis JH. Diamond-blackfan anemia and cyclosporine therapy revisited. J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):176-9. Review.</citation>
    <PMID>10779036</PMID>
  </reference>
  <reference>
    <citation>Bobey NA, Carcao M, Dror Y, Freedman MH, Dahl N, Woodman RC. Sustained cyclosporine-induced erythropoietic response in identical male twins with diamond-blackfan anemia. J Pediatr Hematol Oncol. 2003 Nov;25(11):914-8.</citation>
    <PMID>14608205</PMID>
  </reference>
  <reference>
    <citation>Harris SI, Weinberg JB. Treatment of red cell aplasia with antithymocyte globulin: repeated inductions of complete remissions in two patients. Am J Hematol. 1985 Oct;20(2):183-6.</citation>
    <PMID>3929597</PMID>
  </reference>
  <reference>
    <citation>Roychowdhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant. 1995 Sep;16(3):471-2.</citation>
    <PMID>8535322</PMID>
  </reference>
  <reference>
    <citation>Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol. 1986 Dec;23(4):363-71.</citation>
    <PMID>3098093</PMID>
  </reference>
  <reference>
    <citation>McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, Hoffman R. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med. 1987 Oct 15;317(16):1004-8.</citation>
    <PMID>3116428</PMID>
  </reference>
  <reference>
    <citation>Bejaoui M, Fitouri Z, Sfar MT, Lakhoua R. Failure of immunosuppressive therapy and high-dose intravenous immunoglobulins in four transfusion-dependent, steroid-unresponsive Blackfan-Diamond anemia patients. Haematologica. 1993 Jan-Feb;78(1):38-9.</citation>
    <PMID>8491420</PMID>
  </reference>
  <reference>
    <citation>Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Intravenous gamma-globulin therapy in Diamond-Blackfan anemia. Acta Paediatr Jpn. 1992 Apr;34(2):179-80.</citation>
    <PMID>1621524</PMID>
  </reference>
  <reference>
    <citation>Miceli Sopo S, Pesaresi MA, Pastore M, Stabile A. Intravenous immunoglobulin in Diamond-Blackfan anaemia. Eur J Pediatr. 1990 Aug;149(11):779-80.</citation>
    <PMID>2226550</PMID>
  </reference>
  <reference>
    <citation>Halperin DS, Estrov Z, Freedman MH. Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood. 1989 Apr;73(5):1168-74.</citation>
    <PMID>2649168</PMID>
  </reference>
  <reference>
    <citation>Dunbar CE, Smith DA, Kimball J, Garrison L, Nienhuis AW, Young NS. Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol. 1991 Oct;79(2):316-21.</citation>
    <PMID>1958491</PMID>
  </reference>
  <reference>
    <citation>Gillio AP, Faulkner LB, Alter BP, Reilly L, Klafter R, Heller G, Young DC, Lipton JM, Moore MA, O'Reilly RJ. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood. 1993 Aug 1;82(3):744-51.</citation>
    <PMID>8338944</PMID>
  </reference>
  <reference>
    <citation>Gillio AP, Faulkner LB, Alter BP, Reilly L, Klafter R, Heller G, Young DC, Lipton JM, Moore MA, O'Reilly RJ. Successful treatment of Diamond-Blackfan anemia with interleukin 3. Stem Cells. 1993 Jul;11 Suppl 2:123-30.</citation>
    <PMID>7691318</PMID>
  </reference>
  <reference>
    <citation>Bastion Y, Bordigoni P, Debré M, Girault D, Leblanc T, Tchernia G, Ball S, McGuckin C, Gordon-Smith EC, Békassy A, et al. Sustained response after recombinant interleukin-3 in diamond blackfan anemia. Blood. 1994 Jan 15;83(2):617-8.</citation>
    <PMID>8286756</PMID>
  </reference>
  <reference>
    <citation>Olivieri NF, Feig SA, Valentino L, Berriman AM, Shore R, Freedman MH. Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood. 1994 May 1;83(9):2444-50.</citation>
    <PMID>8167334</PMID>
  </reference>
  <reference>
    <citation>Ball SE, Tchernia G, Wranne L, Bastion Y, Bekassy NA, Bordigoni P, Debré M, Elinder G, Kamps WA, Lanning M, et al. Is there a role for interleukin-3 in Diamond-Blackfan anaemia? Results of a European multicentre study. Br J Haematol. 1995 Oct;91(2):313-8.</citation>
    <PMID>8547067</PMID>
  </reference>
  <reference>
    <citation>Abkowitz JL, Schaison G, Boulad F, Brown DL, Buchanan GR, Johnson CA, Murray JC, Sabo KM. Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis. Blood. 2002 Oct 15;100(8):2687-91.</citation>
    <PMID>12351372</PMID>
  </reference>
  <reference>
    <citation>Akiyama M, Yanagisawa T, Yuza Y, Yokoi K, Ariga M, Fujisawa K, Hoshi Y, Eto Y. Successful treatment of Diamond-Blackfan anemia with metoclopramide. Am J Hematol. 2005 Apr;78(4):295-8.</citation>
    <PMID>15795909</PMID>
  </reference>
  <reference>
    <citation>Leblanc TM, Da Costa L, Marie I, Demolis P, Tchernia G. Metoclopramide treatment in DBA patients: no complete response in a French prospective study. Blood. 2007 Mar 1;109(5):2266-7.</citation>
    <PMID>17312003</PMID>
  </reference>
  <reference>
    <citation>Cynober L, Harris RA. Symposium on branched-chain amino acids: conference summary. J Nutr. 2006 Jan;136(1 Suppl):333S-6S. doi: 10.1093/jn/136.1.333S.</citation>
    <PMID>16365109</PMID>
  </reference>
  <reference>
    <citation>Choudry HA, Pan M, Karinch AM, Souba WW. Branched-chain amino acid-enriched nutritional support in surgical and cancer patients. J Nutr. 2006 Jan;136(1 Suppl):314S-8S. doi: 10.1093/jn/136.1.314S. Review.</citation>
    <PMID>16365105</PMID>
  </reference>
  <reference>
    <citation>Pospisilova D, Cmejlova J, Hak J, Adam T, Cmejla R. Successful treatment of a Diamond-Blackfan anemia patient with amino acid leucine. Haematologica. 2007 May;92(5):e66-7.</citation>
    <PMID>17562599</PMID>
  </reference>
  <reference>
    <citation>Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr. 2006 Jan;136(1 Suppl):227S-31S. doi: 10.1093/jn/136.1.227S. Review.</citation>
    <PMID>16365087</PMID>
  </reference>
  <reference>
    <citation>Pencharz PB, Ball RO. Amino acid needs for early growth and development. J Nutr. 2004 Jun;134(6 Suppl):1566S-1568S. doi: 10.1093/jn/134.6.1566S. Review.</citation>
    <PMID>15173431</PMID>
  </reference>
  <reference>
    <citation>Bernardini P, Fischer JE. Amino acid imbalance and hepatic encephalopathy. Annu Rev Nutr. 1982;2:419-54. Review.</citation>
    <PMID>6138050</PMID>
  </reference>
  <reference>
    <citation>Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther. 2004 Apr 1;19(7):779-88.</citation>
    <PMID>15043519</PMID>
  </reference>
  <reference>
    <citation>Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet. 1988 May 7;1(8593):1015-8.</citation>
    <PMID>2896868</PMID>
  </reference>
  <reference>
    <citation>Pass KA, Lane PA, Fernhoff PM, Hinton CF, Panny SR, Parks JS, Pelias MZ, Rhead WJ, Ross SI, Wethers DL, Elsas LJ 2nd. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr. 2000 Oct;137(4 Suppl):S1-46.</citation>
    <PMID>11044838</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu JM, Leblanc T, Paley C, Kang EM, Leder EJ, Atsidaftos E, Shimamura A, Bessler M, Glader B, Lipton JM; Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008 Sep;142(6):859-76. doi: 10.1111/j.1365-2141.2008.07269.x. Epub 2008 Jul 30.</citation>
    <PMID>18671700</PMID>
  </reference>
  <reference>
    <citation>Cmejlova J, Dolezalova L, Pospisilova D, Petrtylova K, Petrak J, Cmejla R. Translational efficiency in patients with Diamond-Blackfan anemia. Haematologica. 2006 Nov;91(11):1456-64.</citation>
    <PMID>17082006</PMID>
  </reference>
  <reference>
    <citation>Hutson SM, Sweatt AJ, Lanoue KF. Branched-chain [corrected] amino acid metabolism: implications for establishing safe intakes. J Nutr. 2005 Jun;135(6 Suppl):1557S-64S. doi: 10.1093/jn/135.6.1557S. Review. Erratum in: J Nutr. 2005 Aug;135(8):2009.</citation>
    <PMID>15930469</PMID>
  </reference>
  <reference>
    <citation>Lab Advisor(TM); Leucine Measurements in Micromedex (R) Healthcare Series. 2010Thomson Reuters</citation>
  </reference>
  <reference>
    <citation>Jellin JM, Gregory P, Batz F. Pharmacist's letter/ Prescriber's Letter Natural Medicines Comprehensive Database, 3rd ed, Therapeutic Research Faculty, Stockton, CA, 2000.</citation>
  </reference>
  <reference>
    <citation>Braverman ER. The Healing Nutrients Within. New Canaan, CT: Keats Publishing, Inc. 1997; 339</citation>
  </reference>
  <reference>
    <citation>Gilman AG, Rall JW, Nies AD et al (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. Pergamon Press, New York, NY, 1990.</citation>
  </reference>
  <reference>
    <citation>AMA Department of Drugs; AMA Drug Evaluations, 6th ed. American Medical Association, Chicago, IL,1986.</citation>
  </reference>
  <reference>
    <citation>Tietz NE (Ed); Clinical Guide to Laboratory Tests, 3rd ed W. B. Saunders, Philadelphia, PA, 1995.</citation>
  </reference>
  <reference>
    <citation>Henry JB: Clinical Diagnosis and Management by Laboratory Methods, 20th ed. Saunders 2001.</citation>
  </reference>
  <reference>
    <citation>Sax HC, Talamini MA, Fischer JE. Clinical use of branched-chain amino acids in liver disease, sepsis, trauma, and burns. Arch Surg. 1986 Mar;121(3):358-66. Review.</citation>
    <PMID>3080979</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Adrianna Vlachos</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>leucine administration</keyword>
  <keyword>red blood cell transfusion</keyword>
  <keyword>Diamond Blackfan anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Red-Cell Aplasia, Pure</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Anemia, Hypoplastic, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

